Share

New Report Highlights Reveal Future of Insulin Biosimilars

Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...
Share

All About Adrenal: Analyzing Two Years of Research

ENDO_2022_4C When the ENDO 2022 session “Clinical Year in Review: All Things Adrenal” gets underway, Gary Hammer, MD, PhD, will treat attendees to the series of advances that have been made in adrenal science and clinical practice over the last two years, from adrenal homeostasis, glucocorticoid biology, and adrenal insufficiency to Cushing’s, tumors, pheochromocytoma, and more....
Share

Gender-Affirming Care: Bridging the Gap

ENDO_2022_4C As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults.   On the...
Share

Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Share

Hammer Wins Inaugural Endocrine Images Art Competition

Hammer_2020 Gary Hammer, MD, PhD, Millie Schembechler professor of Adrenal Cancer at the University of Michigan in Ann Arbor, Mich., won the Endocrine Society’s Endocrine Images Art Competition, a contest celebrating the beauty of endocrine science. Entries were judged based on aesthetic value and significance to endocrine research. Hammer’s image of the adrenal gland took the top...
Share

Stem Cells Show Promise in Treating Late-Onset Hypogonadism

Directed differentiation of human induced pluripotent (hiPSCs) into Leydig-like cells may be a novel and promising treatment for late-onset hypogonadism (LOH), according to a study recently published in Endocrinology. Researchers led by Takashi Aoi, MD, PhD, of Kobe University in Japan, point out that LOH is characterized by various symptoms, including erectile dysfunction, decreased muscle...